Search

Displaying results 961 - 970 of 2674 in total
  1. Target

    Short transient receptor potential channel 6

    go.drugbank.com/bio_entities/BE0020965
    TargetHumans

    Mediates calcium entry following G(q)-coupled receptor or receptor tyrosine kinase activation, which triggers phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositides and production of diacylglycerol

    Polypeptides: Short transient receptor potential channel 6Synonyms: Transient receptor protein 6
  2. Target

    Neuropeptide Y receptor type 4-2

    go.drugbank.com/bio_entities/BE0024014
    TargetHumans

    G protein-coupled receptor for PPY/pancreatic polypeptide/PP, NPY/neuropeptide Y and PYY/peptide YY that is negatively coupled to cAMP.

    Polypeptides: Neuropeptide Y receptor type 4-2Function: pancreatic polypeptide receptor activity
  3. Target

    T cell receptor gamma variable 9

    go.drugbank.com/bio_entities/BE0025222
    TargetHumans

    V region of the variable domain of T cell receptor (TR) gamma chain that participates in the antigen recognition (PubMed:24600447).

    Polypeptides: T cell receptor gamma variable 9
  4. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549]

  5. Drug

    Taurine

    go.drugbank.com/drugs/DB01956
    ApprovedInvestigationalNutraceutical

    [L1058] The supplements containing taurine were FDA approved by 1984 and they are hypertonic injections composed by cristalline amino acids.[FDA label]

  6. Drug

    Pentetic acid

    go.drugbank.com/drugs/DB14007
    ApprovedInvestigational

    [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469] … DTPA, along with its calcium and zinc trisodium salts, are the only FDA approved agents for the treatment of internal contamination by transuranics.

  7. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    In cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir [FDA … This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including

  8. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy … Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.

    Categories: Substance P/Neurokinin-1 Receptor Antagonist
  9. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469]

  10. Drug

    Azficel-T

    go.drugbank.com/drugs/DB11051
    ApprovedWithdrawn

    Dermal fibroblasts are collected from the post-auricular biopsy tissue and aseptically expanded using standard tissue-culture procedures until sufficient cells for three doses are obtained [FDA Label].